The Latest Psychedelics Articles from Streetwise Reports
Andrew Partheniou (12/20/2022) The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report.
Dr. Elemer Piros (10/27/2022) This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report.
Dr. Elemer Piros (10/06/2022) Read to learn why ROTH Capital Partners gave Atai Life Sciences NV a Buy rating and a target price 10 times its current.
Patrick R. Trucchio (09/27/2022) Treatment of alcohol use disorder with psychedelics plus therapy is effective, according to existing data, and the potential global market is large, noted an H.C. Wainwright & Co. report.
Showing Results: 1 to 4 of 4